Gina Cross
Nurse Practitioner · Charleroi, PANPI 1124387915
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 578 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 578 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$2K
- AstraZeneca$1K
- Bayer$1K
- Vifor Pharma, Inc.$988
- Calliditas Therapeutics US Inc.$691
- Boehringer Ingelheim$649
- plus $4K from 20 others
What the payments were for
- Consulting fees$3754%
- Food & beverage$10,05194%
- Education$2873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 81 | $1,535 |
| AstraZeneca(2 entities) | 58 | $1,280 |
| Bayer | 66 | $1,135 |
| Vifor Pharma, Inc. | 72 | $988 |
| Calliditas Therapeutics US Inc. | 48 | $691 |
| Boehringer Ingelheim | 31 | $649 |
| OPKO Pharmaceuticals, LLC | 34 | $576 |
| Fresenius USA Marketing, Inc. | 28 | $542 |
| Otsuka America Pharmaceutical, Inc. | 26 | $535 |
| Amgen(2 entities) | 27 | $530 |
| Akebia Therapeutics Inc | 27 | $427 |
| Ardelyx, Inc. | 19 | $419 |
| Novartis | 16 | $347 |
| Daiichi Sankyo Inc. | 12 | $291 |
| Mallinckrodt Hospital Products Inc. | 9 | $246 |
| Aurinia Pharma U.S., Inc. | 7 | $131 |
| Nxstage Medical, Inc. | 2 | $101 |
| GSK | 4 | $57 |
| Apellis Pharmaceuticals, Inc. | 2 | $56 |
| Novo Nordisk | 2 | $43 |
| Lilly USA, LLC | 2 | $36 |
| Cycle Pharmaceuticals Inc | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $21 |
| Abbott | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$10,713 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 60 | $161,533 |
| XphozahTenapanor Hcl | 26 | $83,796 |
| VeltassaPatiromer Calcium Sorbitex | 39 | $50,971 |
| AuryxiaFerric Citrate | 44 | $39,627 |
| LokelmaSodium Zirconium Cyclosilicate | 42 | $34,396 |
| FarxigaDapagliflozin Propanediol | 25 | $15,965 |
| KerendiaFinerenone | 12 | $11,783 |
| TradjentaLinagliptin | 13 | $9,588 |
| Sevelamer Carbonate | 77 | $8,139 |
| Cinacalcet Hcl | 21 | $5,045 |
| Midodrine Hcl | 37 | $3,025 |
| Icosapent Ethyl | 13 | $2,806 |
| Calcitriol | 140 | $1,799 |
| Calcium Acetate | 23 | $1,298 |
| Losartan Potassium | 93 | $947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $542 | $161,53360 claims |
| AstraZenecaLokelma, Farxiga | $1,280 | $50,36167 claims |
| Akebia Therapeutics IncAuryxia | $427 | $39,62744 claims |
| BayerKerendia | $1,135 | $11,78312 claims |
| Boehringer IngelheimTradjenta | $649 | $9,58813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Charleroi
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.